Highlights Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Delayed Nasdaq Other stock markets 03:00:21 2024-04-29 pm EDT			5-day change	1st Jan Change
2.4 ^USD	+2.13%		+5.96%	+92.00%

Apr. 16	Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	MT
Apr. 16	Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	Apr. 16	MT
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	Apr. 16	CI
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 09	CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	Apr. 02	CI
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	Mar. 05	CI
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	Mar. 04	CI
Lexaria Bioscience Corp. Announces 7% Weight Loss in Animals Supports in its Next 8-Week Animal Study	Mar. 04	CI
Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial	Mar. 01	CI
Lexaria Bioscience Corp. Submits Investigational New Drug Application	Jan. 30	CI
Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program	Jan. 16	CI
Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 12	CI
Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream	Jan. 11	CI
Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform	Jan. 09	CI
Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide	Jan. 04	CI
Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update	Dec. 07	CI
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study	Nov. 27	CI
Lexaria Bioscience Corp. Reports Earnings Results for the Full Year Ended August 31, 2023	Nov. 20	CI
Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs	23-10-31	CI
Lexaria Enters New Global Exclusive Collaboration and License Agreement with Sulfosyn	23-10-13	CI
Lexaria Bioscience Granted Two Canadian Patents for Nicotine Addiction Treatment Candidate	23-10-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Highlights

Filters